Rationale and design of the prevention of cardiac dysfunction during an adjuvant breast cancer therapy (PRADA) trial

Cardiology (Switzerland)

Volumn 123, Issue 4, 2013, Pages 240-247

  Heck, Siri Lagethon ^a   Gulati, Geeta ^a,e   Ree, Anne Hansen ^a,e   Schulz Menger, Jeanette ^d   Gravdehaug, Berit ^a   Røsjø, Helge ^a,e   Steine, Kjetil ^a,e   Bratland, Åse ^b   Hoffmann, Pavel ^c   Geisler, Jürgen ^a,e   Omland, Torbjørn ^a,e  

^a AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e UNIVERSITY OF OSLO   (Norway)

Author keywords

Breast cancer; Cardiotoxicity; Cardiovascular magnetic resonance; Echocardiography

Indexed keywords

CANDESARTAN; EPIRUBICIN; METOPROLOL; TRASTUZUMAB; TROPONIN I;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CARDIOTOXICITY; CARDIOVASCULAR MAGNETIC RESONANCE; DRUG DOSE TITRATION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LEFT VENTRICULAR DIASTOLIC DYSFUNCTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STUDY DESIGN; TRANSTHORACIC ECHOCARDIOGRAPHY;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; BREAST NEOPLASMS; DIASTOLE; DOUBLE-BLIND METHOD; ECHOCARDIOGRAPHY; FEMALE; HEART FAILURE; HUMANS; MAGNETIC RESONANCE IMAGING; RANDOM ALLOCATION; STATISTICS AS TOPIC; SYSTOLE; VENTRICULAR FUNCTION, LEFT;

EID: 84870298012     PISSN: 00086312     EISSN: 14219751     Source Type: Journal    
DOI: 10.1159/000343622     Document Type: Article

References (35)

1. Ferlay J, Héry C, Autier P, Sankaranarayanan R: Global burden of breast cancer; in Li C (ed): Breast Cancer Epidemiology. New York, Springer, 2010, pp 1-19
2. Jones LW, Haykowsky MJ, Swartz JJ, Douglas PS, Mackey JR: Early breast cancer therapy and cardiovascular injury. J Am Coll Cardiol 2007; 50: 1435-1441 (Pubitemid 47494586)
3. Bird BR, Swain SM: Cardiac toxicity in breast cancer survivors: Review of potential cardiac problems. Clin Cancer Res 2008; 14: 14-24 (Pubitemid 351377973)
4. Schmitz KH, Prosnitz RG, Schwartz AL, Carver JR: Prospective surveillance and management of cardiac toxicity and health in breast cancer survivors. Cancer 2012; 118(8 suppl):2270-2276
5. Menna P, Gonzalez Paz O, Chello M, Covino E, Salvatorelli E, Minotti G: Anthracycline cardiotoxicity. Expert Opin Drug Saf 2012; 11: 21-36
6. Roca-Alonso L, Pellegrino L, Castellano L, Stebbing J: Breast cancer treatment and adverse cardiac events: What are the molecular mechanisms? Cardiology 2012; 122: 253-259
7. Meinardi MT, van Veldhuisen DJ, Gietema JA, Dolsma WV, Boomsma F, van den Berg MP, et al: Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. J Clin Oncol 2001; 19: 2746-2753 (Pubitemid 32441381)
8. Maxwell CB, Jenkins AT: Drug-induced heart failure. American J Health Syst Pharm 2011; 68: 1791-1804
9. Butany J, Ahn E, Luk A: Drug-related cardiac pathology. J Clin Pathol 2009; 62: 1074- 1084
10. Chien KR: Herceptin and the heart - a molecular modifier of cardiac failure. New Engl J Med 2006; 354: 789-790 (Pubitemid 43290916)
11. Crone SA, Zhao YY, Fan L, Gu Y, Minamisawa S, Liu Y, et al: ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 2002; 8: 459-465 (Pubitemid 34546747)
12. Gordon LI, Burke MA, Singh AT, Prachand S, Lieberman ED, Sun L, et al: Blockade of the ERBB2 receptor induces cardiomyocyte death through mitochondrial and reactive oxygen species-dependent pathways. J Biol Chem 2009; 284: 2080-2087
13. Force T, Krause DS, Van Etten RA: Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 2007; 7: 332-344 (Pubitemid 46652481)
14. Darby SC, McGale P, Taylor CW, Peto R: Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: Prospective cohort study of about 300,000 women in US SEER cancer registries. Lancet Oncol 2005; 6: 557-565 (Pubitemid 41051933)
15. Little MP, Tawn EJ, Tzoulaki I, Wakeford R, Hildebrandt G, Paris F, et al: Review and meta- analysis of epidemiological associations between low/moderate doses of ionizing radiation and circulatory disease risks, and their possible mechanisms. Radiat Environ Biophys 2010; 49: 139-153
16. Lee VC, Rhew DC, Dylan M, Badamgarav E, Braunstein GD, Weingarten SR: Meta-analysis: Angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction. Ann Intern Med 2004; 141: 693-704 (Pubitemid 39434842)
17. Schocken DD, Benjamin EJ, Fonarow GC, Krumholz HM, Levy D, Mensah GA, et al: Prevention of heart failure. Circulation 2008;117:2544-2565
18. Minotti G, Salvatorelli E, Menna P: Pharmacological foundations of cardio-oncology. J Pharmacol Exp Ther 2010; 334: 2-8
19. Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M, et al: Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin- converting enzyme inhibition. Circulation 2006; 114: 2474-2481 (Pubitemid 44901520)
20. Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomi G, et al: Anthracycline- induced cardiomyopathy: Clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 2010; 55: 213-220
21. Kalay N, Basar E, Ozdogru I, Er O, Cetinkaya Y, Dogan A, et al: Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 2006; 48: 2258-2262 (Pubitemid 44855419)
22. Nakamae H, Tsumura K, Terada Y, Nakane T, Nakamae M, Ohta K, et al: Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer 2005; 104: 2492-2498 (Pubitemid 41691573)
23. Cadeddu C, Piras A, Mantovani G, Deidda M, Dessi M, Madeddu C, et al: Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment. Am Heart J 2010; 160: 487 e1-e7
24. Bellenger NG, Davies LC, Francis JM, Coats AJ, Pennell DJ: Reduction in sample size for studies of remodeling in heart failure by the use of cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2000; 2: 271-278 (Pubitemid 32048395)
25. Friedrich MG, Sechtem U, Schulz-Menger J, Holmvang G, Alakija P, Cooper LT, et al: Cardiovascular magnetic resonance in myocarditis: A JACC white paper. J Am Coll Cardiol 2009; 53: 1475-1487
26. Wassmuth R, Lentzsch S, Erdbruegger U, Schulz-Menger J, Doerken B, Dietz R, et al: Subclinical cardiotoxic effects of anthracyclines as assessed by magnetic resonance imaging - a pilot study. Am Heart J 2001; 141: 1007-1013 (Pubitemid 32477014)
27. Lightfoot JC, D'Agostino RB Jr, Hamilton CA, Jordan J, Torti FM, Kock ND, et al: Novel approach to early detection of doxorubicin cardiotoxicity by gadolinium-enhanced cardiovascular magnetic resonance imaging in an experimental model. Circ Cardiovasc Imaging 2010; 3: 550-558
28. Senior R, Soman P, Khattar RS, Lahiri A: Improved endocardial visualization with second harmonic imaging compared with fundamental two-dimensional echocardiographic imaging. Am Heart J 1999; 138(1 Pt 1):163-168 (Pubitemid 29331138)
29. Price DJ, Wallbridge DR, Stewart MJ: Tissue Doppler imaging: Current and potential clinical applications. Heart 2000; 84(suppl 2):II11-II18
30. Cho GY, Chan J, Leano R, Strudwick M, Marwick TH: Comparison of two-dimensional speckle and tissue velocity based strain and validation with harmonic phase magnetic resonance imaging. Am J Cardiol 2006; 97: 1661-1666 (Pubitemid 43737037)
31. Monaghan MJ: Role of real time 3D echocardiography in evaluating the left ventricle. Heart 2006; 92: 131-136 (Pubitemid 43021881)
32. Messroghli DR, Greiser A, Frohlich M, Dietz R, Schulz-Menger J: Optimization and validation of a fully-integrated pulse sequence for modified look-locker inversion-recovery (MOLLI) T1 mapping of the heart. JMRI 2007; 26: 1081-1086 (Pubitemid 47548170)
33. Cardinale D, Sandri MT, Martinoni A, Tricca A, Civelli M, Lamantia G, et al: Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol 2000; 36: 517-522
34. Cardinale D, Sandri MT, Colombo A, Colombo N, Boeri M, Lamantia G, et al: Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 2004; 109: 2749-2754 (Pubitemid 38737923)
35. Pituskin E, Haykowsky M, Mackey JR, Thompson RB, Ezekowitz J, Koshman S, et al: Rationale and design of the Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research Trial (MANTICORE 101-Breast): A randomized, placebocontrolled trial to determine if conventional heart failure pharmacotherapy can prevent trastuzumab-mediated left ventricular remodeling among patients with HER2+ early breast cancer using cardiac MRI. BMC Cancer 2011; 11: 318